Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085359172> ?p ?o ?g. }
- W3085359172 endingPage "110737" @default.
- W3085359172 startingPage "110737" @default.
- W3085359172 abstract "To investigate whether triptolide-nanoliposome-APRPG (TP-nanolip-APRPG), a novel sustained-release nano-drug delivery system that targets vascular endothelial cells, could enhance the inhibition of triptolide (TP) on laser-induced choroidal neovascularization (CNV). TP was encapsulated with or without APRPG (Ala-Pro-Arg-Pro-Gly) peptide-modified nanoliposomes. CNV was induced by laser photocoagulation in C57BL/6J mice. One microliter of 10 μg free TP monomer, TP-nanolip containing 10 μg TP, TP-nanolip-APRPG containing 10 μg TP, or an identical volume of PBS was intravitreally injected in mice immediately after laser photocoagulation. Seven days after laser photocoagulation, CNV volumes were calculated in each group. Infiltration of M2 macrophages as well as protein levels of vascular endothelial growth factor (VEGF) and inflammatory factors including ICAM-1 and MCP-1 in the RPE-choroid complex were determined. In vitro assays for cell proliferation, migration, and tube formation were also performed. TP-nanolip-APRPG was successfully synthesized and exhibited good TP delivery and enhanced the cellular uptake of TP in vitro. In vitro studies showed that TP-nanolip-APRPG was a better inhibitor of cell proliferation (31.34 ± 3.89 % vs 41.25 ± 4.67 % vs 53.55 ± 5.76 %), migration (62.60 ± 8.88 vs 104.60 ± 13.32 vs 147.00 ± 13.15), and tube formation (681.26 ± 108.15 vs 926.75 ± 54.01 vs 1189.84 ± 157.14) than TP-nanolip or free TP (all P < 0.05). Intravitreal injections of free TP (77588.10±7719.28 μm3), TP-nanolip (64628.23 ± 5857.96 μm3), and TP-nanolip-APRPG (50880.34 ± 6606.56 μm3) inhibited the development of CNV compared with the PBS control group (120338.07 ± 17428.90 μm3) (P < 0.01, n=6). TP-nanolip-APRPG and TP-nanolip significantly down-regulated the protein levels of VEGF (152.76±19.55 vs 182.24±19.98 vs 208.55±21.93 pg/mg total protein) and inflammatory factors including ICAM-1 (61.69±3.49 vs 72.04±3.49 vs 81.92±4.09 ng/mg total protein) and MCP-1 (40.14±3.50 vs 50.75±4.18 vs 60.27±5.23 pg/mg total protein) compared with the free TP monomer group (all P < 0.05, n=8), which paralleled the decreased infiltration of M2 macrophages in the CNV lesions. Moreover, no influence on retinal morphology and function was observed before or after treatment in each group (P > 0.05, n=6). TP-nanolip-APRPG, a novel sustained-release drug delivery system targeting endothelial cells of CNV lesions, could enhance TP inhibition of the development of CNV without toxicity in the retina, suggesting therapeutic potential for CNV-related diseases in future clinical practice." @default.
- W3085359172 created "2020-09-21" @default.
- W3085359172 creator A5000232278 @default.
- W3085359172 creator A5012191613 @default.
- W3085359172 creator A5012391493 @default.
- W3085359172 creator A5014680510 @default.
- W3085359172 creator A5029497486 @default.
- W3085359172 creator A5049236009 @default.
- W3085359172 creator A5050624639 @default.
- W3085359172 creator A5058111268 @default.
- W3085359172 date "2020-11-01" @default.
- W3085359172 modified "2023-10-16" @default.
- W3085359172 title "Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization" @default.
- W3085359172 cites W1933038751 @default.
- W3085359172 cites W1975238335 @default.
- W3085359172 cites W1984967504 @default.
- W3085359172 cites W1989935936 @default.
- W3085359172 cites W1992891129 @default.
- W3085359172 cites W2000000541 @default.
- W3085359172 cites W2000959104 @default.
- W3085359172 cites W2014928486 @default.
- W3085359172 cites W2021670204 @default.
- W3085359172 cites W2035718304 @default.
- W3085359172 cites W2036279685 @default.
- W3085359172 cites W2037646821 @default.
- W3085359172 cites W2049276881 @default.
- W3085359172 cites W2050019961 @default.
- W3085359172 cites W2057144208 @default.
- W3085359172 cites W2062733305 @default.
- W3085359172 cites W2064684153 @default.
- W3085359172 cites W2066326071 @default.
- W3085359172 cites W2070693151 @default.
- W3085359172 cites W2072234904 @default.
- W3085359172 cites W2073545230 @default.
- W3085359172 cites W2082887801 @default.
- W3085359172 cites W2084740377 @default.
- W3085359172 cites W2091094134 @default.
- W3085359172 cites W2118117784 @default.
- W3085359172 cites W2130301080 @default.
- W3085359172 cites W2170838097 @default.
- W3085359172 cites W2322817475 @default.
- W3085359172 cites W2475717697 @default.
- W3085359172 cites W2768035291 @default.
- W3085359172 cites W2782057573 @default.
- W3085359172 cites W2783029517 @default.
- W3085359172 cites W2784661072 @default.
- W3085359172 cites W2797448045 @default.
- W3085359172 cites W2797455782 @default.
- W3085359172 cites W2896701786 @default.
- W3085359172 cites W2907713512 @default.
- W3085359172 cites W3003483326 @default.
- W3085359172 cites W3036318901 @default.
- W3085359172 cites W3185739311 @default.
- W3085359172 doi "https://doi.org/10.1016/j.biopha.2020.110737" @default.
- W3085359172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32932044" @default.
- W3085359172 hasPublicationYear "2020" @default.
- W3085359172 type Work @default.
- W3085359172 sameAs 3085359172 @default.
- W3085359172 citedByCount "11" @default.
- W3085359172 countsByYear W30853591722020 @default.
- W3085359172 countsByYear W30853591722021 @default.
- W3085359172 countsByYear W30853591722022 @default.
- W3085359172 countsByYear W30853591722023 @default.
- W3085359172 crossrefType "journal-article" @default.
- W3085359172 hasAuthorship W3085359172A5000232278 @default.
- W3085359172 hasAuthorship W3085359172A5012191613 @default.
- W3085359172 hasAuthorship W3085359172A5012391493 @default.
- W3085359172 hasAuthorship W3085359172A5014680510 @default.
- W3085359172 hasAuthorship W3085359172A5029497486 @default.
- W3085359172 hasAuthorship W3085359172A5049236009 @default.
- W3085359172 hasAuthorship W3085359172A5050624639 @default.
- W3085359172 hasAuthorship W3085359172A5058111268 @default.
- W3085359172 hasBestOaLocation W30853591721 @default.
- W3085359172 hasConcept C123012128 @default.
- W3085359172 hasConcept C153911025 @default.
- W3085359172 hasConcept C167734588 @default.
- W3085359172 hasConcept C178790620 @default.
- W3085359172 hasConcept C185592680 @default.
- W3085359172 hasConcept C190283241 @default.
- W3085359172 hasConcept C202751555 @default.
- W3085359172 hasConcept C2777025900 @default.
- W3085359172 hasConcept C2778271429 @default.
- W3085359172 hasConcept C2779820397 @default.
- W3085359172 hasConcept C2780394083 @default.
- W3085359172 hasConcept C2780827179 @default.
- W3085359172 hasConcept C2781164371 @default.
- W3085359172 hasConcept C2781359195 @default.
- W3085359172 hasConcept C502942594 @default.
- W3085359172 hasConcept C55493867 @default.
- W3085359172 hasConcept C71924100 @default.
- W3085359172 hasConcept C86803240 @default.
- W3085359172 hasConcept C98274493 @default.
- W3085359172 hasConceptScore W3085359172C123012128 @default.
- W3085359172 hasConceptScore W3085359172C153911025 @default.
- W3085359172 hasConceptScore W3085359172C167734588 @default.
- W3085359172 hasConceptScore W3085359172C178790620 @default.
- W3085359172 hasConceptScore W3085359172C185592680 @default.
- W3085359172 hasConceptScore W3085359172C190283241 @default.